AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Trial: 11292113
Drug: Inhaled Ems
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Inhaled Ems salt (cough group)
Trial: 8619450
Drug: Two 400-mg
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Two 400-mg doses of artesunate followed by two doses of mefloquine (750 mg immediately and 500 mg 12 hr later)
Trial: 8619450
Drug: Four 200-mg
RxNorm normalized name: Four-Way
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Four 200-mg doses of artesunate given 12 hr apart followed by a mefloquine regimen similar to Group I
Trial: 8619450
Drug: Group II
RxNorm normalized name: Platelet group IIa
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Group II (four 200-mg doses of artesunate followed by mefloquine)
Trial: 8619450
Drug: Group I
RxNorm normalized name: Platelet group IIa
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Group I (two 400-mg doses of artesunate followed by mefloquine)
Trial: 3891239
Drug: Amcinonide ointment
RxNorm normalized name: Amcinonide Ointment
DrugBank: Amcinonide (DB00288)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Amcinonide ointment applied twice daily for two weeks
Trial: 3891239
Drug: Betamethasone dipropionate
RxNorm normalized name: Betamethasone Dipropionate
DrugBank: Betamethasone (DB00443)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Betamethasone dipropionate ointment applied twice daily for two weeks
Trial: 30031995
Drug: Activity based
RxNorm normalized name: Activated Charcoal
DrugBank: Activated charcoal (DB09278)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Activity based group therapy (1 hour duration, once a week for 4 weeks)
Trial: 30031995
Drug: Activity based
RxNorm normalized name: Activated Charcoal
DrugBank: Activated charcoal (DB09278)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Activity based group therapy
Trial: 22743149
Drug: Duloxetine 60
RxNorm normalized name: duloxetine 60 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Duloxetine 60 mg/day for 16 weeks
Trial: 20483194
Drug: Topical anesthesia
RxNorm normalized name: Gelato Anesthetic
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Topical anesthesia using liposomal lidocaine
Trial: 20483194
Drug: Nurse-administered tactile
RxNorm normalized name: ethanol
DrugBank: Ethanol (DB00898)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Nurse-administered tactile stimulation
Trial: 10468689
Drug: EC‐ASA 100
FDA approved: no
EMA approved: no
PMDA approved: no
Description: EC‐ASA 100 mg/day
Trial: 10468689
Drug: Plain ASA
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Plain ASA 100 mg/day
Trial: 1836097
Drug: Low-dose intravenous
RxNorm normalized name: ethinyl estradiol
DrugBank: Ethinylestradiol (DB00977)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: Low-dose intravenous nitroglycerin infusion
Trial: 7201725
Drug: Tetravalent (1,
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Tetravalent (1, 3, 4, 12F) polysaccharide pneumococcal vaccine
Trial: 7201725
Drug: Tetravalent (14,
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Tetravalent (14, 18C, 19F, 23F) vaccine
Trial: 7201725
Drug: Pentadecavalent vaccine
RxNorm normalized name: Pertussis vaccine
DrugBank: Pertussis vaccine (DB15274)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Pentadecavalent vaccine (1, 3, 4, 6A, 7F, 8, 9N, 11A, 12F, 14, 15F, 18C, 19F, 23F)
Trial: 19581537
Drug: GEM (standard
FDA approved: no
EMA approved: no
PMDA approved: no
Description: GEM (standard treatment) 1,000 mg/m(2)/30 minutes
Trial: 19581537
Drug: GEM FDR
RxNorm normalized name: menthol
DrugBank: Menthol (DB14123)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: GEM FDR 1,500 mg/m(2)/150 minutes
Trial: 19581537
Drug: GEMOX (GEM
FDA approved: no
EMA approved: no
PMDA approved: no
Description: GEMOX (GEM 1,000 mg/m(2)/100 minutes + oxaliplatin 100 mg/m(2)/day 2 every 14 days)
Trial: 20421430
Drug: 1.1% amino
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 1.1% amino acid solution
Trial: 8739021
Drug: Pravastatin 10
RxNorm normalized name: pravastatin 10 mg oral tablet
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Pravastatin 10 mg daily
Trial: 9583841
Drug: Usual diet
RxNorm normalized name: phentermine hydrochloride Oral Capsule [T-Diet]
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Usual diet (UD) with 1.2‐1.5 g protein/kg body wt
Trial: 9583841
Drug: Chicken diet
RxNorm normalized name: Chicken
DrugBank: Chicken (DB10519)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Chicken diet (CD) with 1.2‐1.5 g protein/kg body wt
Trial: 9583841
Drug: Low-protein diet
RxNorm normalized name: low-density polyethylene
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Low-protein diet (LPD) with 0.5‐0.8 g protein/kg body wt
Trial: 7539186
Drug: Laser therapy
RxNorm normalized name: Monistat Simple Therapy
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Laser therapy (holmium and diode lasers)
Trial: 6732159
Drug: Cimetidine treatment
RxNorm normalized name: Cimetidine
DrugBank: Cimetidine (DB00501)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Cimetidine treatment (34 patients)
Trial: 29371061
Drug: Standard care
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Standard care (monthly mailings and matched podcasts on non-weight related topics)
Trial: 22412140
Drug: Salvage chemotherapy
RxNorm normalized name: menthol
DrugBank: Menthol (DB14123)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Salvage chemotherapy (SLC) plus best supportive care (BSC)
Trial: 22412140
Drug: Salvage chemotherapy
RxNorm normalized name: menthol
DrugBank: Menthol (DB14123)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Salvage chemotherapy (SLC)
Trial: 20151421
Drug: Sustained-release cytarabine
RxNorm normalized name: Cytarabine
DrugBank: Cytarabine (DB00987)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: Sustained-release cytarabine
Trial: 20151421
Drug: Sustained-release cytarabine
RxNorm normalized name: Cytarabine
DrugBank: Cytarabine (DB00987)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: Sustained-release cytarabine (lumbar administration)
Trial: 20151421
Drug: Sustained-release cytarabine
RxNorm normalized name: Cytarabine
DrugBank: Cytarabine (DB00987)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: Sustained-release cytarabine (ventricular administration)
Trial: 20151421
Drug: Methotrexate (lumbar
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Methotrexate (lumbar administration)
Trial: 20151421
Drug: Methotrexate (ventricular
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Methotrexate (ventricular administration)
Trial: 15677733
Drug: Positive airway
RxNorm normalized name: VersaPAP Positive Airway Pressure Device
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Positive airway pressure treatment after a minimum period of 8 weeks
Trial: 12062776
Drug: Comprehensive Validation
RxNorm normalized name: Easy Care First Aid Kit - Comprehensive KIT
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Comprehensive Validation Therapy with 12-Step (CVT + 12S)
Trial: 9416309
Drug: Glycerol administration
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Glycerol administration
Trial: 15990220
Drug: Solifenacin 5
RxNorm normalized name: solifenacin 5 mg oral tablet
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Solifenacin 5 or 10 mg
Trial: 15990220
Drug: Tolterodine extended
RxNorm normalized name: tolterodine Extended Release Oral Capsule
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Tolterodine extended release (ER) 4 mg
Trial: 12619955
Drug: Short acting
RxNorm normalized name: Prolixin (short acting injection) 2.5 MG/ML Injectable Solution
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Short acting beta agonists as needed for mild episodic asthma
Trial: 12619955
Drug: Bronchodilators with
RxNorm normalized name: Primatene with ephedrine Pill
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Bronchodilators with daily maintenance treatment (low dose inhaled steroids, cromolyn, oral theophylline, leukotriene antagonists) for mild persistent asthma
Trial: 12619955
Drug: Inhaled steroids
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Inhaled steroids with long acting beta agonists for moderate persistent asthma
Trial: 12619955
Drug: Inhaled steroids,
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Inhaled steroids, long acting beta agonists with or without theophylline for severe persistent asthma
Trial: 12619955
Drug: Oral prednisolone
RxNorm normalized name: prednisolone Oral Solution
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Oral prednisolone on alternate days if symptoms are not well controlled
Trial: 12619955
Drug: Cromolyn, short
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Cromolyn, short or long acting beta agonists, or leukotriene antagonists for exercise-induced bronchoconstriction
Trial: 12619955
Drug: Maintenance treatment
RxNorm normalized name: Dental Resources Perio Maintenance Rinse
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Maintenance treatment for children with seasonal asthma starting 2 weeks in advance and continued throughout the season
Trial: 21722580
Drug: Electrical stimulation
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Electrical stimulation therapy
Trial: 20735271
Drug: RTS,S/AS01(E) coadministered
FDA approved: no
EMA approved: no
PMDA approved: no
Description: RTS,S/AS01(E) coadministered with EPI vaccines at 0, 1, and 2 months (3 doses)
Trial: 20735271
Drug: RTS,S/AS01(E) coadministered
FDA approved: no
EMA approved: no
PMDA approved: no
Description: RTS,S/AS01(E) coadministered with EPI vaccines at 0, 1, and 7 months (2 doses)
Trial: 29213269
Drug: EPI vaccines
RxNorm normalized name: 8-epi-cyanocobalamin
DrugBank: 8-epi-Cyanocobalamin (DB14092)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: EPI vaccines only
Trial: 2312776
Drug: metoprolol CR/ZOK
FDA approved: no
EMA approved: no
PMDA approved: no
Description: metoprolol CR/ZOK 50 mg
Trial: 2878680
Drug: atenolol 50
RxNorm normalized name: atenolol 50 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: atenolol 50 mg
Trial: 2155948
Drug: metoprolol CR/ZOK
FDA approved: no
EMA approved: no
PMDA approved: no
Description: metoprolol CR/ZOK 100 mg
Trial: 27551051
Drug: Endocrine treatment
RxNorm normalized name: Hongo Killer Treatment
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Endocrine treatment
Trial: 31479846
Drug: Yoga exercise
RxNorm normalized name: ethanol
DrugBank: Ethanol (DB00898)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Yoga exercise intervention (8 weeks, twice a week instructor-led and once a week home practice)
Trial: 24237100
Drug: Chiropractic care
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Chiropractic care including spinal manipulative therapy and massage
Trial: 16148848
Drug: RIX4414 (pooled
FDA approved: no
EMA approved: no
PMDA approved: no
Description: RIX4414 (pooled vaccine groups)
Trial: 16148848
Drug: RIX4414 (post-dose
FDA approved: no
EMA approved: no
PMDA approved: no
Description: RIX4414 (post-dose 1 to 14 days post-dose 2)
Trial: 11020919
Drug: Speech therapy
RxNorm normalized name: Monistat Simple Therapy
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Speech therapy with active participation of mothers
Trial: 11020919
Drug: Speech therapy
RxNorm normalized name: Monistat Simple Therapy
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Speech therapy without active participation of mothers (control group)
Trial: 8543554
Drug: Sertraline (mean
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Sertraline (mean dose 87 mg/day)
Trial: 8543554
Drug: Desipramine (mean
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Desipramine (mean dose 110 mg/day)
Trial: 1805284
Drug: Aspartame chocolate
RxNorm normalized name: Aspartame
DrugBank: Aspartame (DB00168)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Aspartame chocolate drink (80 mg)
Trial: 1805284
Drug: Sucrose chocolate
RxNorm normalized name: Sucrose
DrugBank: Sucrose (DB02772)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Sucrose chocolate drink (50 g)
Trial: 23789288
Drug: Intravenous omega-3
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Intravenous omega-3 polyunsaturated fatty acids infusion
Trial: 23789288
Drug: 0.9% saline
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 0.9% saline solution infusion (Control)
Trial: 21368667
Drug: Leech therapy
RxNorm normalized name: Monistat Simple Therapy
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Leech therapy (2 to 4 locally applied leeches)
Trial: 21368667
Drug: Topical diclofenac
RxNorm normalized name: diclofenac Topical Solution
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Topical diclofenac (30-day course)
Trial: 17659263
Drug: 2 g
RxNorm normalized name: Molds 2 g
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 2 g of sarcosine daily
Trial: 17659263
Drug: 1 g
RxNorm normalized name: Molds 1 g
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 1 g of sarcosine daily
Trial: 17659263
Drug: Both doses
RxNorm normalized name: Bothrops atrox venom
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Both doses of sarcosine
Trial: 10969521
Drug: i.v. tramadol
FDA approved: no
EMA approved: no
PMDA approved: no
Description: i.v. tramadol (1 mg/kg)
Trial: 8851611
Drug: Cefetamet pivoxil
RxNorm normalized name: Cefetamet pivoxil
DrugBank: Cefetamet pivoxil (DB18915)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Cefetamet pivoxil (500 mg)
Trial: 8851611
Drug: Cefuroxime axetil
RxNorm normalized name: Cefuroxime Axetil
DrugBank: Cefuroxime (DB01112)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Cefuroxime axetil (125 mg and 250 mg)
Trial: 6380356
Drug: Theophylline (therapeutic
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Theophylline (therapeutic serum concentration averaged 13 mg/L, range 4.0 to 22.1)
Trial: 1763589
Drug: Oxycodone (5
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Oxycodone (5 mg)
Trial: 1632533
Drug: Ketorolac (10
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Ketorolac (10 mg)
Trial: 27401638
Drug: Intensive lipid-lowering
RxNorm normalized name: guggul lipids
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Intensive lipid-lowering treatment (ezetimibe/simvastatin 10/40 mg, n=34)
Trial: 27401638
Drug: Control statin
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Control statin treatment (pravastatin 20 mg, n=36)
Trial: 12700955
Drug: Felodipine ER
RxNorm normalized name: Felodipine ER
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Felodipine ER 5 mg once daily
Trial: 12700955
Drug: Felodipine ER
RxNorm normalized name: Felodipine ER
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Felodipine ER 2.5 mg once daily
Trial: 10355807
Drug: Sequential neuromotor
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Sequential neuromotor examination at 3, 6, and 12 months
Trial: 10355807
Drug: Sequential neuromotor
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Sequential neuromotor examination at 12 months
Trial: 10355807
Drug: Sequential neuromotor
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Sequential neuromotor examination
Trial: 10355807
Drug: Positive neonatal
RxNorm normalized name: Foreskin fibroblast (neonatal)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Positive neonatal urine drug screen for both cocaine and opiates
Trial: 10355807
Drug: Positive maternal
RxNorm normalized name: salicylic acid
DrugBank: Salicylic acid (DB00936)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Positive maternal drug screens for concurrent cocaine and opiate use
Trial: 8918563
Drug: Oral prednisolone
RxNorm normalized name: prednisolone Oral Solution
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Oral prednisolone (starting dose 100 mg/day for 20 weeks)
Trial: 8918563
Drug: Intravenous immunoglobulin
RxNorm normalized name: Intravenous immunoglobulin (IVIg)
DrugBank: Human immunoglobulin G (DB00028)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Intravenous immunoglobulin (1 g/kg body weight for 2 consecutive days every 3 weeks, repeated six times)
Trial: 29327055
Drug: Nab-paclitaxel, 125
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Nab-paclitaxel, 125 mg/m2
Trial: 29327055
Drug: Paclitaxel, 90
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Paclitaxel, 90 mg/m2
Trial: 25265658
Drug: Standard cardioprotective
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Standard cardioprotective therapy
Trial: 2695862
Drug: Pirenzepine (100
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Pirenzepine (100 mg/die/os for 12 weeks)
Trial: 606771
Drug: Chemically disrupted
RxNorm normalized name: Membrane-disrupting peptide ep-100
DrugBank: Onvitrelin ucalontide (DB19183)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Chemically disrupted influenza A/New Jersey/76 virus vaccine
Trial: 606771
Drug: Whole‐virus influenza
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Whole‐virus influenza A/New Jersey/76 virus vaccine
Trial: 606771
Drug: Preparation from
RxNorm normalized name: cranberry preparation
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Preparation from Wyeth Laboratories
Trial: 606771
Drug: Preparation from
RxNorm normalized name: cranberry preparation
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Preparation from Parke, Davis and Company
Trial: 606771
Drug: Preparation from
RxNorm normalized name: cranberry preparation
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Preparation from Merrell‐National Laboratories
Trial: 20127139
Drug: AZD6244 (100
FDA approved: no
EMA approved: no
PMDA approved: no
Description: AZD6244 (100 mg twice daily)
Trial: 20127139
Drug: Capecitabine (1,250
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Capecitabine (1,250 mg/m2 twice daily for 2 weeks followed by 1-week rest)
Trial: 19169187
Drug: Desvenlafaxine 200-400
RxNorm normalized name: Desvenlafaxine
DrugBank: Desvenlafaxine (DB06700)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Desvenlafaxine 200-400 mg/day
Trial: 17113759
Drug: Amisulpride (200-600
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Amisulpride (200-600 mg/day)
Trial: 17113759
Drug: Olanzapine (5-15
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Olanzapine (5-15 mg/day)
Trial: 9389397
Drug: Control (no
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Control (no further treatment after pancreaticoduodenectomy)
Trial: 3360052
Drug: N-acetylcysteine (NAC)
DrugBank: Acetylcysteine (DB06151)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: N-acetylcysteine (NAC) 200 mg i.v.
Trial: 3360052
Drug: N-acetylcysteine (NAC)
DrugBank: Acetylcysteine (DB06151)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: N-acetylcysteine (NAC) 400 mg p.o.
Trial: 31969368
Drug: Isoniazid (INH)
RxNorm normalized name: Isoniazid
DrugBank: Isoniazid (DB00951)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Isoniazid (INH) 10 mg/kg plus pyridoxine for 12 months
Trial: 16412796
Drug: Oral estrogen
RxNorm normalized name: estrogens
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Oral estrogen therapy (O-ET, 2 mg oral micronized 17beta estradiol daily)
Trial: 16412796
Drug: Transdermal estrogen
RxNorm normalized name: estrogens
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Transdermal estrogen therapy (T-ET, 17beta estradiol 1.5 mg gel daily)
Trial: 15256300
Drug: Psycho-educational intervention
RxNorm normalized name: hydroquinone
DrugBank: Hydroquinone (DB09526)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Psycho-educational intervention (individual treatment session, two follow-up calls, information booklet)
Trial: 11748518
Drug: Diltiazem (once-daily
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Diltiazem (once-daily oral for at least 2 weeks)
Trial: 3530302
Drug: 0.50 mg
RxNorm normalized name: EVEROLIMUS 0.50 mg ORAL TABLET
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 0.50 mg triazolam
Trial: 26268138
Drug: RP‐1127 (glyburide
FDA approved: no
EMA approved: no
PMDA approved: no
Description: RP‐1127 (glyburide for injection)
Trial: 16200849
Drug: 0.05 U/kg
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 0.05 U/kg insulin (group A)
Trial: 16200849
Drug: 0.1 U/kg
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 0.1 U/kg insulin (group B)
Trial: 16200849
Drug: 0.05 U/kg
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 0.05 U/kg insulin and 0.1 U/kg insulin
Trial: 8737030
Drug: Combination treatment
RxNorm normalized name: Hongo Killer Treatment
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Combination treatment (daytime glibenclamide and evening NPH insulin)
Trial: 8737030
Drug: Intensive insulin
RxNorm normalized name: INSULIN
DrugBank: Insulin beef (DB09456)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Intensive insulin treatment (rapid acting insulin before meals and NPH insulin at bedtime)
Trial: 3904543
Drug: IV aminophylline
RxNorm normalized name: Aminophylline
DrugBank: Aminophylline (DB01223)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: IV aminophylline loading dose
Trial: 3904543
Drug: Oral aminophylline
RxNorm normalized name: Aminophylline
DrugBank: Aminophylline (DB01223)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Oral aminophylline loading dose
Trial: 16915380
Drug: Lorazepam (0.038
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Lorazepam (0.038 mg/kg)
Trial: 30770536
Drug: Live music
RxNorm normalized name: fecal microbiota, live Enema [Rebyota]
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Live music therapy during rehabilitation
Trial: 27682068
Drug: Oral Fusidic
RxNorm normalized name: fusidate
DrugBank: Fusidic acid (DB02703)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Oral Fusidic Acid (FA) in combination with Oral Rifampin (RIF)
Trial: 27682068
Drug: Standard-of-Care (SOC)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Standard-of-Care (SOC) intravenous antibiotics
Trial: 24748637
Drug: Oral vitamin
RxNorm normalized name: vitamin A Oral Tablet
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Oral vitamin D2 50,000 IU monthly for 24 weeks (Ca+D)
Trial: 24748637
Drug: Calcium carbonate
RxNorm normalized name: Calcium Carbonate
DrugBank: Calcium carbonate (DB06724)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Calcium carbonate as limestone (approximately 938 mg elemental calcium twice daily) alone (Ca)
Trial: 18212316
Drug: Conventional diabetes
RxNorm normalized name: Diabetic Tussin EX
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Conventional diabetes therapy with a focus on weight loss by lifestyle change
Trial: 16180593
Drug: Arm therapy
RxNorm normalized name: SOMBRA Warm Therapy 3 % / 3 % Topical Gel
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Arm therapy programme (15‐20 45‐min sessions) based on repetition of unilateral and symmetrical bilateral tasks